This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: National Vaccine and Serum Institute (Nvsi). Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Zehua Lei: Innovator in Vaccine Development
Introduction
Zehua Lei is a prominent inventor based in Beijing, China. He has made significant contributions to the field of vaccine development, particularly in the fight against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). His innovative work has the potential to impact public health on a global scale.
Latest Patents
Zehua Lei holds a patent for a recombinant severe respiratory syndrome coronavirus 2 RBD trimer protein vaccine. This vaccine is capable of generating broad-spectrum cross-neutralization activity against various SARS-CoV-2 epidemic strains. The invention provides a recombinant RBD trimer protein that serves as an antigen, supplemented with an adjuvant to immunize an organism. This process enables the generation of high-titer neutralizing antibodies targeting multiple SARS-CoV-2 strains, which can be utilized for treating and preventing SARS-CoV-2 infections and coronavirus disease 2019.
Career Highlights
Zehua Lei is associated with the National Vaccine and Serum Institute, where he continues to advance his research and development efforts. His work is crucial in addressing the challenges posed by emerging infectious diseases.
Collaborations
Zehua Lei collaborates with notable colleagues, including Qiming Li and Yu Liang, who contribute to his research endeavors. Their combined expertise enhances the potential for innovative solutions in vaccine technology.
Conclusion
Zehua Lei's contributions to vaccine development exemplify the critical role of inventors in addressing global health challenges. His innovative approaches and collaborative efforts are paving the way for advancements in the prevention and treatment of infectious diseases.